Skip to main content
Figure 4 | Journal of Translational Medicine

Figure 4

From: Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy

Figure 4

IL-18 improves only the antitumor effect of time-dependent drugs. (A) Combination therapy with IL-18 improves the survival benefit offered by paclitaxel and topotecan alone and restricts ascites accumulation (left). C57BL/6 mice were injected i.p. with 5 × 106 ID8-Vegf cells on day 0 and subsequently treated with the indicated types of treatment. Mice treated with the combination of paclitaxel plus IL-18 had a significantly prolonged survival compared to the respective monotherapies (p < 0.01; control n = 23, IL-18 alone n = 22, paclitaxel n = 14, IL-18 plus paclitaxel n = 13). Combination therapy significantly restricted ascites accumulation (right) compared to the respective monotherapies as measured by the increase in the animal weight. The asterisks show data points where the difference in ascites accumulation is significant (Student's test, P < 0.001). (B) The combination of topotecan plus IL-18 also significantly prolonged the survival comparing to the respective monotherapies (p < 0.01; control n = 10, IL-18 alone n = 10, topotecan alone n = 9, IL-18 plus paclitaxel n = 10). Combination therapy significantly restricted ascites accumulation (right). The addition of IL-18 to carboplatin (C) or gemcitabine (D) did not significantly improve survival (left) or restrict ascites accumulation (right). IL-18/carboplatin experiment: Control n = 9, IL-18 n = 9, carboplatin n = 9, IL-18 plus carboplatin n = 9. IL-18/gemcitabine experiment: Control n = 10, IL-18 n = 10, gemcitabine n = 9, IL-18 plus gemcitabine n = 10.

Back to article page